AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Marti Technologies shares rise 1.97% premarket after positive clinical trial results for QTORIN™ rapamycin.
ByAinvest
Thursday, Aug 14, 2025 8:37 am ET1min read
Marti Technologies Inc. rose 1.97% in premarket trading. The company announced that its Phase 3 SELVA trial evaluating QTORIN™ rapamycin for microcystic lymphatic malformations has completed enrollment, exceeding the target by over 25%, with top-line results expected in the first quarter of 2026. Additionally, top-line results for the Phase 2 TOIVA trial evaluating QTORIN™ rapamycin for cutaneous venous malformations are on track for the fourth quarter of 2025. QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for these conditions. The company also plans to announce a third clinical indication for QTORIN™ rapamycin and a second QTORIN™ platform candidate before year-end 2025.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet